If You Invested in ONWARD Medical NV (ONWRY)

ONWARD Medical N.V. (US ADR: ONWRY, Euronext: ONWD) is a neurotechnology company focused on developing and commercializing therapies designed to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities. According to the company’s disclosures, its technologies are built on decades of scientific discovery, preclinical research, and clinical studies conducted at hospitals, rehabilitation clinics, and neuroscience laboratories.

The company has developed a therapy platform known as ARC Therapy. A key product based on this platform is the ARC-EX® System, a non-invasive external spinal cord stimulation system. Company materials state that ARC-EX Therapy is indicated to improve hand strength and sensation in adults with chronic, non-progressive neurological deficits resulting from incomplete spinal cord injury at levels C2–C8. The ARC-EX System delivers programmed, transcutaneous electrical spinal cord stimulation, used in conjunction with functional task practice in clinics and, where cleared, with take-home exercises in the home.

ONWARD Medical reports that the ARC-EX System is cleared for commercial sale in the United States and Europe. In the US, it has received clearance from the Food and Drug Administration (FDA), and in Europe it has obtained CE Mark certification under the European Union Medical Device Regulation (MDR). The company notes that ARC-EX is described as the first and only FDA-cleared technology demonstrated to improve hand strength and sensation in people with spinal cord injury, and that it has been recognized in external publications such as TIME magazine’s Best Inventions and Fast Company’s World Changing Ideas.

Beyond external stimulation, ONWARD Medical is developing an investigational implantable neuromodulation platform called the ARC-IM® System. Company announcements describe ARC-IM as an implanted system designed to address unmet needs such as blood pressure instability after spinal cord injury. Clinical feasibility studies reported by the company and published in journals including Nature and Nature Medicine show that ARC-IM Therapy is being evaluated for its ability to improve hemodynamic stability, reduce hypotensive symptoms, and manage blood pressure instability after SCI. The system includes an implanted neurostimulator and a thoracic lead optimized for placement in a region of the spinal cord associated with blood pressure regulation.

ONWARD Medical also reports work on an investigational ARC-BCI® system, which pairs its spinal cord stimulation technology with a brain-computer interface (BCI). According to company updates, this combination is being studied to enable thought-driven movement after spinal cord injury. The company has announced multiple clinical feasibility implants of ARC-BCI technology as part of ongoing research programs.

The company states that the ARC Therapy platform has received 10 Breakthrough Device Designations from the FDA, underscoring the regulatory focus on its spinal cord stimulation technologies. ARC-EX Therapy is supported by clinical evidence from studies such as the Up-LIFT pivotal trial and the Pathfinder2 study, which, according to the company’s press releases, reported improvements in strength or function, quality of life, upper body sensation, trunk control, and balance for participants with SCI when ARC-EX Therapy was combined with activity-based rehabilitation.

ONWARD Medical is headquartered in the Netherlands. It also reports having a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The company’s ordinary shares are listed on Euronext Paris, Brussels, and Amsterdam under the ticker ONWD, and its American Depositary Receipts (ADRs) trade on the OTCQX market under the symbol ONWRY.

From a capital markets perspective, ONWARD Medical has disclosed multiple equity financings via private placements and capital increases on Euronext markets. The company has highlighted participation from institutional and sector-focused investors and has indicated that proceeds are intended to support product development, clinical studies, regulatory activities for ARC-IM, and commercialization of ARC-EX in the United States, Europe, and selected other geographies. It has also noted the establishment of a sponsored Level 1 ADR program on OTCQX.

According to its public communications, ONWARD Medical positions itself at the intersection of neurotechnology, medical devices, and rehabilitation science, with a focus on addressing key challenges faced by people living with spinal cord injury, such as impaired hand function, mobility limitations, and blood pressure instability. Its pipeline spans external and implantable spinal cord stimulation systems and BCI-enabled approaches, all centered on ARC Therapy.

Business focus and technology

ONWARD Medical’s core business centers on the research, development, regulatory approval, and commercialization of medical devices and therapies for SCI and related movement disabilities. The ARC-EX System represents its first commercial product, while ARC-IM and ARC-BCI are described as investigational and not yet available for commercial use. The company emphasizes clinical evidence, regulatory milestones, and collaborations with leading neurorehabilitation and neurosurgical research centers as key elements of its strategy.

Regulatory and clinical milestones

Company announcements reference several notable regulatory and clinical milestones, including:

• FDA clearance for the ARC-EX System in the US, including expanded indication for home use.
• CE Mark certification for the ARC-EX System, enabling commercialization in the European Union and facilitating regulatory pathways in other countries that recognize CE Marking.
• FDA approval of an Investigational Device Exemption (IDE) for the ARC-IM System, allowing initiation of the Empower BP global pivotal study to assess safety and effectiveness for managing blood pressure instability after SCI.
• Simultaneous publications in Nature and Nature Medicine describing clinical feasibility results and mechanistic insights related to ARC-IM Therapy and blood pressure regulation after spinal cord injury.

Stock and listing information

ONWARD Medical N.V. is listed on Euronext Paris, Brussels, and Amsterdam under the ticker ONWD. Its US American Depositary Receipts trade on the OTCQX market under the symbol ONWRY. The ONWRY ADRs provide US-based investors with an avenue to gain exposure to the company’s equity, as described in its public investor communications.

FAQs about ONWARD Medical (ONWRY)

• What does ONWARD Medical do?
  ONWARD Medical develops and commercializes neurotechnology therapies intended to restore movement, function, and independence in people with spinal cord injuries and other movement disabilities. Its work centers on ARC Therapy, which includes external and implantable spinal cord stimulation systems.
• What is ARC-EX Therapy?
  ARC-EX Therapy uses the ARC-EX System, a non-invasive external spinal cord stimulation device that delivers programmed, transcutaneous electrical stimulation. According to the company, it is indicated to improve hand strength and sensation in adults with chronic, non-progressive neurological deficits from incomplete spinal cord injury at levels C2–C8, when used with functional task practice.
• Where is the ARC-EX System available?
  Company disclosures state that the ARC-EX System is cleared for commercial sale in the United States and Europe. It has FDA clearance in the US and CE Mark certification in the European Union, with use in clinics and, where authorized, in the home.
• What is the ARC-IM System?
  The ARC-IM System is an investigational implantable neuromodulation platform developed by ONWARD Medical. It is designed to deliver targeted spinal cord stimulation to address unmet needs such as blood pressure instability after spinal cord injury. It is being evaluated in clinical studies and is not yet available for commercial use.
• How does ONWARD Medical use brain-computer interface (BCI) technology?
  ONWARD Medical is developing an investigational ARC-BCI system that can be paired with ARC-IM to restore thought-driven movement after spinal cord injury. The company has reported multiple feasibility implants of this BCI-enabled approach as part of ongoing clinical research.
• What regulatory designations has ONWARD Medical received?
  The company reports that ARC Therapy has been awarded 10 Breakthrough Device Designations from the US Food and Drug Administration, reflecting regulatory interest in its potential to address serious conditions related to spinal cord injury.
• Where is ONWARD Medical headquartered?
  ONWARD Medical states that it is headquartered in the Netherlands, with a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts.
• On which exchanges does ONWARD Medical trade?
  ONWARD Medical’s ordinary shares trade on Euronext Paris, Brussels, and Amsterdam under the ticker ONWD. Its American Depositary Receipts trade on the OTCQX market in the United States under the symbol ONWRY.
• Is ONWARD Medical focused only on spinal cord injury?
  Company communications emphasize spinal cord injury as a primary focus, including hand function, mobility, and blood pressure instability after SCI. They also reference exploration of potential indications such as Parkinson’s disease in early feasibility work with the ARC-IM System.
• Are all ONWARD Medical products commercially available?
  No. According to the company, the ARC-EX System is cleared for commercial sale in the US and Europe. Other devices and therapies, including ARC-IM and ARC-BCI, are described as investigational and not available for commercial use.